• The API is modified to resist rapid degradation by the DPP-4 enzyme.

• Structural constraints are introduced to stabilize the alpha-helix structure of the peptide, which increases receptor binding affinity and further protects against enzymatic breakdown.

• A "tail" is attached that binds reversibly to human serum albumin
• Next-generation transient permeability enhancers (TPE) or cell-penetrating peptides (CPPs) are added to increase bioavailability from ~1% offered by SNAC up to 5-10%.

• Specific enzyme inhibitors are added to neutralize digestive enzymes in the immediate vicinity of the dissolving pill.
• Tablets are enterically coated to target absorption in the small intestine rather than the stomach

Contact us for details of the current stage of R&D for this masterpiece development. Objective: To enhance consumers' experience and wellness from weekly injection pain to weekly painless comfort.

Zeptide Pharma is a pioneering biotechnology company leading the transition from injectable metabolic therapies to highly effective, patient-friendly oral treatments. We are the premier developer of the next-generation GLP-1 pill, engineered to deliver powerful metabolic control and weight management in a convenient once-weekly weight loss pill.

By utilizing our proprietary albumin-binding peptide formulation alongside advanced permeation enhancers, we have solved the historic challenges of oral peptide delivery. Our flagship oral GLP-1 tablet provides the extended half-life and sustained efficacy of traditional injectables, all within a single weekly dose.

At Zeptide Pharma, our mission is to redefine obesity and diabetes care by delivering the ultimate no-injection weight loss medication. As a leader in oral GLP-1 receptor agonist research, we are dedicated to improving patient compliance, expanding treatment accessibility, and shaping the future of long-acting oral therapeutics.